Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Core Insights - Pharvaris is advancing its late-stage development of deucrictibant, an oral bradykinin B2 receptor antagonist, aimed at treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][14] - The company presented data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the efficacy and safety of deucrictibant in both prophylactic and on-demand treatment settings [2][5] Prophylaxis - The CHAPTER-1 open-label extension study demonstrated long-term safety and efficacy of oral deucrictibant for prophylaxis in HAE, with participants experiencing sustained attack reduction and improved health-related quality of life (HRQoL) [5][6] - All participants reported clinically meaningful improvements in HRQoL, maintained up to week 62 of the study [5] - The ongoing CHAPTER-3 Phase 3 study is designed to evaluate the efficacy and safety of a once-daily, oral deucrictibant extended-release tablet for HAE prophylaxis [5][4] On-Demand Treatment - The RAPIDe-2 extension study provided evidence of the long-term safety and efficacy of oral deucrictibant for treating HAE attacks, with a median time to onset of symptom relief of 1.1 hours and 97.8% of attacks achieving symptom relief within 12 hours [10][7] - Deucrictibant was well tolerated, with no treatment-related adverse events reported, and 89.2% of attacks that achieved symptom resolution at 24 hours were treated with a single dose [10][8] - The RAPIDe-3 study is the first Phase 3 on-demand study to explore 'end-of-progression' as a new pre-specified endpoint, which is significant for HAE patients [2][5] Expansion Beyond HAE - Pharvaris is exploring the potential of deucrictibant beyond HAE, with ongoing studies validating a novel kinin biomarker assay for characterizing bradykinin-mediated pathologies [9][16] - A real-world survey indicated that patients prescribed long-term prophylaxis (LTP) experienced more mild attacks and better HRQoL compared to those on on-demand treatment (ODT) alone, supporting the importance of both treatment modalities in HAE management [10]